Analytical Data
-
Gene name
ACVR2B
-
简介
ACVR2B is a type II member of the TGF-β family of receptor Serine/Threonine kinases. ACVR2B binds to activins and growth differentiation factors (GDF), which in turn activate type I receptors, activating downstream molecule SMAD2/3[1]. ACVR2B Protein, Cynomolgus (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 116 amino acids (S28-M143).
- Application
-
Alternative Names
Activin receptor type-2B; Activin receptor type IIB; ACTR-IIB; ACVR2B
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
EHH16502
-
Expression Region
S28-M143
-
Protein Length
Partial
-
Molecular Weight
54-62 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR2B, or Activin A receptor type IIB, is a member of the transforming growth factor-beta (TGF-β) superfamily of receptors, which plays a critical role in various biological processes, including muscle growth, development, and inflammation. In recent years, research has focused on the therapeutic potential of ACVR2B modulation, particularly in the context of muscle wasting diseases and age-related sarcopenia. Studies have shown that the inhibition of ACVR2B signaling can lead to increased muscle mass and improved functional outcomes, making it a promising target for interventions aimed at counteracting muscle degeneration. Scientists have developed recombinant proteins, such as ACVR2B-Fc fusion proteins, to block the receptor's activity, thus promoting muscle hypertrophy and enhancing physical performance. Additionally, ACVR2B's involvement in metabolic regulation and its interactions with other signaling pathways underscore its importance in health and disease. The ongoing exploration of ACVR2B-focused therapies is paving the way for innovative approaches to treat conditions characterized by muscle loss and to improve the overall quality of life in aging populations or individuals with chronic illnesses.
